Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.94 USD
-0.96 (-1.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $71.96 +0.02 (0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth D Momentum B VGM
Zacks News
What's in the Cards for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.
Baxter International (BAX) Q3 Earnings: What's in Store?
by Zacks Equity Research
Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.
Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.
Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.
Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?
by Zacks Equity Research
Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.
What to Expect From Thermo Fisher (TMO) in Q3 Earnings
by Zacks Equity Research
Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.
Henry Schein (HSIC) Inks Distribution Agreement with Terason
by Zacks Equity Research
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
Will PBM Slowdown Hamper Express Scripts (ESRX) Q3 Earnings?
by Zacks Equity Research
Lackluster performance in PBM product network and services segment is likely to mar Express Scripts' (ESRX) revenues in the third quarter.
Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?
by Zacks Equity Research
We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.
Can CR Bard (BCR) Spring a Surprise This Earnings Season?
by Zacks Equity Research
We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.
Here's Why Investors Should Sell Patterson Companies Now
by Zacks Equity Research
Rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for Patterson Companies (PDCO).
Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?
by Zacks Equity Research
ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.
Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe
by Zacks Equity Research
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
Henry Schein Closes Merritt Buyout, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) is consistently trying to expand its Animal Health business.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Henry Schein MicroMD Software Gets ONC-Health IT Certificate
by Zacks Equity Research
Henry Schein's (HSIC) MicroMD receives ONC-Health IT Certificate from Drummond Group, boosting the company's technology and value-added service business.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact
by Zacks Equity Research
Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.
Henry Schein (HSIC) Tops Q2 Earnings and Revenues Estimate
by Zacks Equity Research
Henry Schein (HSIC) rides high on all four segments in Q2 delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions.